Lessons learned from subretinal implant

Clinician researcher speaks to lessons learned from experience with subretinal visual implant

Lessons learned from subretinal implant
Cheryl Guttman Krader
Cheryl Guttman Krader
Published: Monday, April 29, 2019
In March, 2019, shareholders of Retina Implant AG resolved to dissolve the company. Therefore, Retina Implant Alpha AMS, the company’s subretinal visual implant, will no longer be available for patients. Looking back, however, valuable information can be gleaned from experience with the electronic retinal prosthesis and its earlier generation version (Retina Implant Alpha IMS), said Katarina Stingl MD at the annual meeting of the Association for Research in Vision and Ophthalmology in Vancouver, Canda. Dr Stingl, University of Tübingen, Tübingen, Germany, has 12 years of clinical experience with the subretinal visual implants involving patients implanted in clinical trials and post-commercialisation. She highlighted four issues. First, the subretinal implant can provide low vision restoration to patients with complete blindness from photoreceptor degeneration. The caveat, which was Dr Stingl’s second point, is that there are individual differences in outcomes. Third, it was seen that foveal eccentricity (subfoveal versus parafoveal implant location) matters. Lastly, Dr Stingl said that the subretinal implant had a good clinical safety profile.
Tags: ARVO 2019
Latest Articles
ESCRS Today 2025: Happy Anniversaries!

ESCRS celebrates milestones with pioneers in IOLs, LASIK, femtosecond lasers, and corneal transplantation.

Read more...

ESCRS Today 2025: A Congress for Everyone

From YOs to families, the ESCRS Annual Meeting embraces full participation through inclusivity.

Read more...

ESCRS Today 2025: All Eyes on Innovation

Watching out for obstacles and opportunities

Read more...

Beyond the Numbers

Empowering patient participation fosters continuous innovation in cataract surgery.

Read more...

Thinking Beyond the Surgery Room

Practice management workshop focuses on financial operations and AI business applications.

Read more...

Aid Cuts Threaten Global Eye Care Progress

USAID closure leads retreat in development assistance.

Read more...

Supplement: ESCRS Clinical Trends Series: Presbyopia

Read more...

Debate: FS-LASIK or KLEx for Hyperopia?

FS-LASIK has more of a track record, but KLEx offers advantages.

Read more...

Four AI Applications Ready for Practice

Commercial offerings may save time, improve practice and research.

Read more...

Perioperative Medication Regimens for Cataract Surgery

Randomised controlled clinical trial results provide evidence-based guidance.

Read more...